4.8 Article

Muscular dystrophies

Journal

LANCET
Volume 381, Issue 9869, Pages 845-860

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)61897-2

Keywords

-

Funding

  1. European Union
  2. UK Medical Research Council
  3. Wellcome Trust
  4. Association Francaise Contre les Myopathies
  5. Muscular Dystrophy Campaign
  6. Great Ormond Street Hospital Biomedical Research Centre
  7. Muscular Dystrophy Association USA
  8. GlaxoSmithKline
  9. Trophos
  10. British Heart Foundation
  11. AVI BioPharma
  12. PTC Therapeutics
  13. Parent Project NL
  14. SMA Europe
  15. Italian Telethon
  16. MRC [MR/K000608/1] Funding Source: UKRI
  17. Medical Research Council [MR/K000608/1] Funding Source: researchfish

Ask authors/readers for more resources

Muscular dystrophies are a heterogeneous group of inherited disorders that share similar clinical features and dystrophic changes on muscle biopsy. An improved understanding of their molecular bases has led to more accurate definitions of the clinical features associated with known subtypes. Knowledge of disease-specific complications, implementation of anticipatory care, and medical advances have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected people. A better understanding of the mechanisms underlying the molecular pathogenesis of several disorders and the availability of preclinical models are leading to several new experimental approaches, some of which are already in clinical trials. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, and therapeutic developments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available